Company intelligence / Profile preview

Neuronano

Not specified, but likely Lund or vicinity (see NRC address), Sweden

Ownership: Private
Employees: ~18
Development stage: Other

Overview

Neuronano has developed innovative DBS electrodes designed to adapt to brain movement, improving tissue compatibility and neural contact. Their products aim to provide safer, more stable brain stimulation for neurological disease, minimizing damage and irritation. Product appears to be in advanced prototype, clinical development, or limited commercial stage but not large-scale commercial launch.

Therapeutic areas: Neurology
Modalities: Device
Industry: Implantable Medical Devices

Beyond the preview

Go deeper on Neuronano.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Neuronano.

Explore the full profile